Congress should work on legislation allowing the FDA to fast-track the approval of some drugs already on the market in other developed countries, according to one researcher attached to a west coast free market think tank.
As the matter of prescription drug prices continues to generate debate, and some federal government action, one consumer advocate is warning the Food and Drug Administration (FDA) has loosened rules over interactions between physicians and pharmaceutical companies.
Feedback is continuing to flow in the FDA following the publication of a draft policy document on the future of combination products.